UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000008565
Receipt number R000010067
Scientific Title Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-road
Date of disclosure of the study information 2012/08/01
Last modified on 2018/08/07 21:01:19

No. Disposal Last modified on Item of update
1 Insert 2012/07/30 14:49:55
2 Update 2013/02/19 18:26:20 Primary outcomes
Key secondary outcomes
Key secondary outcomes
3 Update 2014/08/30 17:13:40 TEL
Email
TEL
Email
Email1
4 Update 2015/08/30 10:18:03 Recruitment status
5 Update 2017/02/02 01:34:57 Publication of results
6 Update 2018/02/14 00:25:58 Name of primary person or sponsor
Organization
7 Update 2018/02/14 00:38:47 Last follow-up date
8 Update 2018/08/07 20:59:45 Recruitment status
Date trial data considered complete
Date analysis concluded
Publication of results
9 Update 2018/08/07 21:01:19 Primary outcomes